MedinCell S.A. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was EUR 9.89 million compared to EUR 4.09 million a year ago. Net loss was EUR 29.5 million compared to EUR 24.81 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.9 EUR | -3.25% | +4.20% | +106.94% |
05-09 | Medincell: share price rises on resumption of trading | CF |
05-08 | CAC40: remains in green in a neglected market | CF |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+106.94% | 461M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- MEDCL Stock
- News MedinCell S.A.
- MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023